Harrow (HROW) Convertible Debt (2010 - 2016)

Harrow's (HROW) quarterly Convertible Debt came in at $914000.0 in Q3 2016, up 20.58% quarter-over-quarter from $758000.0 in Q2 2016.

Harrow (HROW) Convertible Debt (2010 - 2016) Analysis & Trends

Harrow's Convertible Debt history runs 3 years deep, the most recent figure standing at $914000.0 for Q3 2016.

On a quarterly basis, Convertible Debt changed N/A year-over-year to $914000.0 in Q3 2016; TTM through Sep 2016 was $914000.0, a N/A change from a year earlier, with the FY2016 full-year figure at $914000.0, changed N/A from the prior year.
Convertible Debt advanced to $914000.0 in Q3 2016 per HROW's latest filing, from $758000.0 in the prior quarter.
Across five years, Convertible Debt topped out at $914000.0 in Q3 2016 and bottomed at $758000.0 in Q2 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn
10	Harrow	1.56 Bn	1.47 Bn	27.05 Mn

Download Data